Physician profile
Khalid Soherwardy
NPI 1386625564
$1,010.23
in general payments reported to CMS, 2019-2025
20 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $18.39 · 2021: $131 · 2022: $202 · 2023: $95.83 · 2024: $189 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $308.33 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $101.31 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $77.61 | 2019-2025 | Repatha |
| Lilly USA, LLC | $71.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $61.51 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $57.63 | 2024-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $47.55 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $46.62 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $34.77 | 2022 | |
| Eisai INC. | $30.93 | 2021-2022 | |
| Astellas Pharma US INC | $24.98 | 2025 | Veozah |
| Mylan Specialty L.P. | $23.71 | 2021 | |
| Phathom Pharmaceuticals, INC. | $21.89 | 2024 | Voquezna |
| Gilead Sciences, INC. | $18.39 | 2020 | |
| Amarin Pharma, INC. | $16.81 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $15.01 | 2024 | Dexcom G6 Transmitter |
| Lucid Diagnostics INC. | $14.41 | 2024 | |
| Arbor Pharmaceuticals, INC. | $13.44 | 2019 | |
| Allergan, INC. | $12.34 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Soherwardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.